Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Non-Current Deffered Revenue: 2019-2025

Historic Non-Current Deffered Revenue for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to $15.2 million.

  • Nurix Therapeutics' Non-Current Deffered Revenue fell 49.18% to $15.2 million in Q3 2025 from the same period last year, while for Aug 2025 it was $15.2 million, marking a year-over-year decrease of 49.18%. This contributed to the annual value of $26.2 million for FY2024, which is 41.79% down from last year.
  • As of Q3 2025, Nurix Therapeutics' Non-Current Deffered Revenue stood at $15.2 million, which was down 29.88% from $21.6 million recorded in Q2 2025.
  • In the past 5 years, Nurix Therapeutics' Non-Current Deffered Revenue registered a high of $77.7 million during Q1 2021, and its lowest value of $10.2 million during Q3 2023.
  • Over the past 3 years, Nurix Therapeutics' median Non-Current Deffered Revenue value was $26.1 million (recorded in 2023), while the average stood at $26.0 million.
  • As far as peak fluctuations go, Nurix Therapeutics' Non-Current Deffered Revenue slumped by 75.35% in 2023, and later soared by 191.50% in 2024.
  • Nurix Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $59.0 million in 2021, then plummeted by 39.05% to $36.0 million in 2022, then grew by 25.15% to $45.0 million in 2023, then slumped by 41.79% to $26.2 million in 2024, then tumbled by 49.18% to $15.2 million in 2025.
  • Its Non-Current Deffered Revenue stands at $15.2 million for Q3 2025, versus $21.6 million for Q2 2025 and $24.2 million for Q1 2025.